Biological and Functional Properties of Wedelolactone in Human Chronic Diseases
  • Ramachandran Vinyagam1, Pradeep Kumar2, Kyung Eun Lee1,3, Baojun Xu4, Muhammad Nurul Matin5,*, Sang Gu Kang1,3,*
1 Department of Biotechnology, Institute of Biotechnology, College of Life and Applied Science, Yeungnam University, Gyeongsan, Gyeongbuk, 38541, Korea
2 Department of Forestry, North Eastern Regional Institute of Science and Technology, Nirjuli, 791109, India
3 Stemforce, 313 Institute of Industrial Technology, Yeungnam University, Gyeongsan, Gyeongbuk, 38541, Korea
4 Food Science and Technology Program, Beijing Normal University-Hong Kong Baptist University, United International College, Zhuhai, 519000, China
5 Department of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, 6205, Bangladesh
* Corresponding Authors: Muhammad Nurul Matin. Email: nmatin@ru.ac.bd; Sang Gu Kang. Email: kangsg@ynu.ac.kr
Received 05 August 2020; Accepted 28 September 2020; Issue published 20 November 2020
Abstract
Medicinal herbs are well known and studied over the past millennia in most of the developing countries as a rational means of treatment against various diseases and disorders. Wedelolactone (WDL), a major bioactive compound in Eclipta prostrata L (Eclipta alba L), has been reported with potential benefits in human health against chronic diseases. However, a comprehensive study on WDL pharmacological benefits in various ailments, to the best of our knowledge, is not yet reported. Thereof, the present review provides the recent therapeutic applications in reference to biological and functional activities against major human chronic diseases, including cardiovascular, cancer, diabetes mellitus, liver disease, Alzheimer’s disease, and androgenetic alopecia. In this study, we collected all the relevant experimental information on WDL from Scientific databases such as PubMed, Web of Science, Science Direct, and Google Scholar. Conclusively, WDL is recognized as a key anti-oxidant with both specific regulator and inhibitor of major drug targetable proteins in human chronic diseases and disorders. Hence, WDL as a novel therapeutic bioactive molecule is advised to explore further for relevant pharmacological activities.
Keywords
Wedelolactone; Eclipta alba L; Ecliptaprostrata L; bioactivity; bioavailability
Cite This Article
Vinyagam, R., Kumar, P., Lee, K. E., Xu, B., Matin, M. N. et al. (2021). Biological and Functional Properties of Wedelolactone in Human Chronic Diseases. Phyton-International Journal of Experimental Botany, 90(1), 1–15.
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.